LifeMD’s (LFMD) “Overweight” Rating Reaffirmed at Cantor Fitzgerald

LifeMD (NASDAQ:LFMD)‘s stock had its “overweight” rating reiterated by equities research analysts at Cantor Fitzgerald in a report released on Tuesday, Benzinga reports. They currently have a $15.00 price target on the stock. Cantor Fitzgerald’s target price would indicate a potential upside of 191.26% from the stock’s current price.

Other analysts also recently issued reports about the stock. B. Riley reaffirmed a “buy” rating and set a $12.00 price objective on shares of LifeMD in a report on Tuesday, May 21st. BTIG Research lifted their target price on shares of LifeMD from $13.00 to $14.00 and gave the stock a “buy” rating in a research report on Tuesday, April 23rd. HC Wainwright reiterated a “buy” rating and issued a $12.00 target price on shares of LifeMD in a research report on Friday, May 10th. Finally, KeyCorp decreased their target price on shares of LifeMD from $12.00 to $10.00 and set an “overweight” rating on the stock in a research report on Thursday, July 11th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $12.17.

LifeMD Price Performance

Shares of NASDAQ LFMD traded down $0.17 during mid-day trading on Tuesday, reaching $5.15. 53,948 shares of the company were exchanged, compared to its average volume of 824,388. LifeMD has a 52 week low of $3.46 and a 52 week high of $12.88. The company has a quick ratio of 0.94, a current ratio of 0.99 and a debt-to-equity ratio of 10.83. The stock has a market capitalization of $215.05 million, a PE ratio of -6.95 and a beta of 1.24. The company’s 50 day moving average price is $6.61 and its 200 day moving average price is $8.12.

LifeMD (NASDAQ:LFMD) last posted its quarterly earnings data on Wednesday, August 7th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.06). The firm had revenue of $50.66 million for the quarter, compared to the consensus estimate of $48.47 million. During the same period in the prior year, the company earned ($0.23) earnings per share. Sell-side analysts forecast that LifeMD will post -0.25 earnings per share for the current fiscal year.

Hedge Funds Weigh In On LifeMD

Several hedge funds and other institutional investors have recently modified their holdings of LFMD. Quest Partners LLC bought a new stake in LifeMD during the second quarter worth about $31,000. Tower Research Capital LLC TRC boosted its stake in LifeMD by 266.3% during the fourth quarter. Tower Research Capital LLC TRC now owns 4,605 shares of the company’s stock worth $38,000 after acquiring an additional 3,348 shares in the last quarter. EntryPoint Capital LLC bought a new stake in LifeMD during the first quarter worth about $89,000. Los Angeles Capital Management LLC bought a new stake in LifeMD during the second quarter worth about $88,000. Finally, The Manufacturers Life Insurance Company bought a new stake in LifeMD during the second quarter worth about $93,000. Hedge funds and other institutional investors own 35.52% of the company’s stock.

About LifeMD

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.